Introduction In recent decades,numerous indicators for early detection and monitoring of hepatocellular carcinoma(HCC)have been suggested and published in reputable journals.These markers have gained recognition and e...Introduction In recent decades,numerous indicators for early detection and monitoring of hepatocellular carcinoma(HCC)have been suggested and published in reputable journals.These markers have gained recognition and endorsement from prominent international associations such as the European Association for the Study of the Liver(EASL),the Asian Pacific Association for the Study of the Liver(APASL),as well as national professional organizations like the American Association for the Study of Liver Diseases(AASLD),among others.展开更多
There is a very urgent need and clinical demand of robust biomarkers in cancer screening,especially in early hepatocellular carcinoma(HCC)surveillance as outlined by various professional international associations as ...There is a very urgent need and clinical demand of robust biomarkers in cancer screening,especially in early hepatocellular carcinoma(HCC)surveillance as outlined by various professional international associations as the European Association for the study of the Liver(EASL),or the Asian Pacific Association for the Study of the Liver(APASL)and national professional organisations as the American Association for the Study of Liver Diseases(AASLD),besides others.Newest data on primarily HCC is still depicting this cancer entity as the sixth most frequently diagnosed cancer,with over 900,000 new cases and over 830,000 deaths worldwide(1).This type of cancer,therefore,remains at the forefront of malignant diseases.Thus,every element of patient management,including early diagnosis and prognosis of treatment response and survival,is a challenge.展开更多
基金funded by the Deutsche Forschungsgemeinschaft (DFG,German Research Foundation),grant number 410853455 to Miroslaw T.Kornekgrant number 411345524 to Veronika Lukacs-Kornek.
文摘Introduction In recent decades,numerous indicators for early detection and monitoring of hepatocellular carcinoma(HCC)have been suggested and published in reputable journals.These markers have gained recognition and endorsement from prominent international associations such as the European Association for the Study of the Liver(EASL),the Asian Pacific Association for the Study of the Liver(APASL),as well as national professional organizations like the American Association for the Study of Liver Diseases(AASLD),among others.
基金This publication was funded by the Deutsche Forschungsgemeinschaft(DFG,German Research Foundation),grant number 410853455 to MTK and grant number 411345524 to VLK.
文摘There is a very urgent need and clinical demand of robust biomarkers in cancer screening,especially in early hepatocellular carcinoma(HCC)surveillance as outlined by various professional international associations as the European Association for the study of the Liver(EASL),or the Asian Pacific Association for the Study of the Liver(APASL)and national professional organisations as the American Association for the Study of Liver Diseases(AASLD),besides others.Newest data on primarily HCC is still depicting this cancer entity as the sixth most frequently diagnosed cancer,with over 900,000 new cases and over 830,000 deaths worldwide(1).This type of cancer,therefore,remains at the forefront of malignant diseases.Thus,every element of patient management,including early diagnosis and prognosis of treatment response and survival,is a challenge.
